Merck lays out vision for women's health spinout Organon, with some special plans for its $9B windfall
As Merck prepares to launch its women’s health spinoff Organon next month, the leadership teams at both companies showed off their business development plans Monday. And based on the way Merck tells it, there’s a lot to like for the newco, even if it’s not quite for them.
Organon’s products while as a Merck subsidiary accounted for roughly $6.6 billion in 2020 sales, Merck said Monday, led by efforts in contraceptive and biosimilar franchises. That figure will likely stay the same for 2021, falling in the estimated $6.1 to $6.4 billion range.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.